@article{ATM26298,
author = {Na-Yi Yuan Wu and Xiaoyun Zhang and Tangyuan Chu and Songlin Zhu and Yuping Deng and Yi Zhou and Ying Wang and Xueheng Zhao and Lu Liu and Chao Fang and Yang Wang and Yu-Ligh Liou and Jingting Cai and Jing Wang},
title = {High methylation of ZNF582 in cervical adenocarcinoma affects radiosensitivity and prognosis},
journal = {Annals of Translational Medicine},
volume = {7},
number = {14},
year = {2019},
keywords = {},
abstract = {Background: Our previous study demonstrated hypermethylation of the ZNF582 gene in cervical cancer, but its prognostic value in cervical cancer, especially in cervical adenocarcinoma (CAC), remains unclear. The present study aimed to investigate the value of ZNF582 gene methylation for diagnosis and prediction of radiochemotherapy sensitivity and prognosis in CAC.
Methods: We first determined ZNF582 methylation levels using quantitative methylation-specific PCR in a training set. Disease-free survival and overall survival (DFS and OS) rates were estimated using the Kaplan-Meier method. A Cox regression model was used to assess the prognostic significance of ZNF582 gene methylation in CAC patients. Immunohistochemistry was used to test ZNF582 protein expression in CAC tissues, and an MTT assay evaluated the sensitivity of Hela cells (with or without ZNF582 transfection) to radiation and chemotherapy.
Results: The ZNF582 gene showed a higher level of methylation in the CAC group than in the noncancer group, and patients negative for ZNF582 methylation had worse prognoses. We also found that ZNF582 methylation levels were reduced in concomitant chemo-radio-therapy (NCRT) patients compared with that in non-NCRT patients. Methylation-negative status was correlated with high ZNF582 protein expression, and ZNF582 protein overexpression could increase resistance to radiation and chemotherapy in Hela cells.
Conclusions: Aberrant high methylation of ZNF582 may be a potential biomarker for CAC detection and prognosis monitoring. Overexpression of ZNF582 protein could increase CAC chemoradiotherapy resistance.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/26298}
}